Federal Register / Vol. 79, No. 216 / Friday, November 7, 2014 / Notices 66407 

moot. Here, while various controlled 

substances were seized, the Government 

subsequently provided registrant with 

the opportunity to transfer the 

controlled substances to a registered 

successor in interest. See 21 U.S.C. 

§ 824(g). Thus, to the extent the 

controlled substances had any market 

value—which appears highly unlikely 

anyway given that they were in 

prescription vials and not sealed 

commercial containers—the 

Government disclaimed any interest in 

them. Registrant’s failure to respond to 

the Government’s offer itself constitutes 

a waiver of any claim to title to the 

drugs. Thus, there is no need to issue a 

decision on the merits to adjudicate the 

issue of title to the drugs. 

To the extent the issuance of the 

Immediate Suspension has harmed 

Registrant’s reputation and may result 

in his having to report this action on 

future applications for a DEA 

registration or a state license, Registrant 

was provided with the opportunity to 

request a hearing and challenge the 

basis of the Government’s action. 

Registrant did not, however, seek to do 

so. See Richard C. Quigley, 79 FR 50945, 

50947 (2014) (rejecting Government’s 

contention that ISO case was not moot 

because of potential harm to physician’s 

reputation when physician did not 

request a hearing). 

It is acknowledged that several federal 

appeals courts have held that ‘‘the mere 

possibility of adverse collateral 

consequences is sufficient to preclude a 

finding of mootness.’’ In re Surrick, 338 

F.3d 224, 230 (3d Cir. 2003) (quoting 

Dailey v. Vought Aircraft Co., 141 F.3d 

224, 228 (5th Cir. 1998)). But in those 

cases, which involved sanctions 

imposed by courts on attorneys, the 

person who was sanctioned at least 

cared enough to litigate. Not so here. So 

too, this case stands in contrast to those 

cases where the Agency has ruled on the 

validity of a suspension order 

notwithstanding that a registrant 

allowed his/her registration to expire 

and failed to file a renewal application. 

See Lockridge, 71 FR at 77797 (holding 

case not moot where registrant subject 

to ISO did not allow registration to 

expire until after receiving adverse 

recommended decision from ALJ); see 

also Nirmal Saran & Nisha Saran, 73 FR 

7827, 7835 n.29 (2008) (holding case not 

moot where during proceeding, 

registrants’ registrations expired but 

registrants asserted that they intended to 

remain in professional practice and had 

attempted to renew their registrations 

online but been prevented from doing 

so). Accordingly, I conclude that this 

case is moot. See Tin T. Win, 78 FR 

52802 (2013) (holding ISO proceeding 

moot where physician, who allowed her 

registration to expire, failed to request a 

hearing and no controlled substances 

had been seized); Robert Charles Ley, 76 

FR 20033 (2011) (holding ISO 

proceeding moot where physician 

eventually waived his right to a hearing 

and no controlled substances had been 

seized). 

Order 

Pursuant to the authority vested in me 

by 21 U.S.C. § 824(a), as well as 28 CFR 

0.100(b) and 0.104, I order that the 

Order to Show Cause and Immediate 

Suspension of Registration issued to 

Martin L. Korn, M.D., be, and it hereby 

is, dismissed. This Order is effective 

immediately. 

Dated: October 23, 2014. 

Thomas M. Harrigan, 

Deputy Administrator. 

[FR Doc. 2014–26447 Filed 11–6–14; 8:45 am] 

BILLING CODE 4410–09–P 

JUSTICE DEPARTMENT 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Alltech 

Associates, Inc. 

ACTION: Notice of registration. 

SUMMARY: Alltech Associates, Inc., 

applied to be registered as a 

manufacturer of certain basic classes of 

controlled substances. The DEA grants 

Alltech Associates, Inc. registration as a 

manufacturer of those controlled 

substances. 

SUPPLEMENTARY INFORMATION: By notice 

dated May 2, 2014, and published in the 

Federal Register on May 15, 2014, 79 

FR 27936, Alltech Associates, Inc., 2051 

Waukegan Road, Deerfield, Illinois 

60015, applied to be registered as a 

manufacturer of certain basic classes of 

controlled substances. No comments or 

objections were submitted to this notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Alltech Associates, Inc., to manufacture 

the basic classes of controlled 

substances is consistent with the public 

interest and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. The DEA investigated the 

company’s maintenance of effective 

controls against diversion by inspecting 

and testing the company’s physical 

security systems, verified the company’s 

compliance with state and local laws, 

and reviewed the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above-named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances listed:– 

Controlled substance Schedule 

Methcathinone (1237) .................. I 

N-Ethylamphetamine (1475) ........ I 

N,N-Dimethylamphetamine (1480) I 

4-Methylaminorex (cis isomer) 

(1590).

I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

2C-T-7 (2,5-Dimethoxy-4-(n)- 

propylthiophenethylamine) 

(7348).

I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

2C-T-2 (2-(4-Ethylthio-2,5- 

dimethoxyphenyl)ethanamine) 

(7385).

I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

2,5-Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-N-ethylamphetamine (7404).I 

3,4-Methylenedioxymethamphetamine (7405).I 

4-Methoxyamphetamine (7411) ... I 

5-Methoxy-N-Ndimethyltryptamine (7431).I 

Alpha-methyltryptamine (7432) .... I 

Bufotenine (7433) ......................... I 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

5-Methoxy-N,Ndiisopropyltryptamine (7439).I 

N-Ethyl-1-phenylcyclohexylamine 

(7455).

I 

1-(1-Phenylcyclohexyl)pyrrolidine 

(7458).

I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

2C-E (2-(2,5-Dimethoxy-4- 

ethylphenyl)ethanamine) (7509).

I 

2C-H (2-(2,5- 

Dimethoxyphenyl)ethanamine) 

(7517).

I 

2C-I (2-(4-lodo-2,5- 

dimethoxyphenyl)ethanamine) 

(7518).

mstockstill on DSK4VPTVN1PROD with NOTICES

66408 Federal Register / Vol. 79, No. 216 / Friday, November 7, 2014 / Notices 

Controlled substance Schedule 

2C-C (2-(4-Chloro-2,5- 

dimethoxyphenyl)ethanamine 

(7519).

I 

2C-T-4 (2-(4-Isopropylthio)-2,5- 

dimethoxyphenyl)ethanamine) 

(7532).

I 

Dihydromorphine (9145) ............... I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Methamphetamine (1105) ............ II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

1- 

Piperidinocyclohexanecarbonitrile (8603).

II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Ecgonine (9180) ........................... II 

Meperidine intermediate-B (9233) II 

Morphine (9300) ........................... II 

Noroxymorphone (9668) .............. II 

The company plans to manufacture 

high purity drug standards used for 

analytical applications only in clinical, 

toxicological, and forensic laboratories, 

and for distribution to its customers. 

Dated: October 23, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–26448 Filed 11–6–14; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Agency Information Collection 

Activities; Submission for OMB 

Review; Comment Request; Equal 

Access to Justice Act 

ACTION: Notice. 

SUMMARY: The Department of Labor 

(DOL) is submitting the information 

collection request (ICR) titled, ‘‘Equal 

Access to Justice Act,’’ to the Office of 

Management and Budget (OMB) for 

review and approval for continued use, 

without change, in accordance with the 

Paperwork Reduction Act of 1995 

(PRA), 44 U.S.C. 3501 et seq. Public 

comments on the ICR are invited. 

DATES: The OMB will consider all 

written comments that agency receives 

on or before December 8, 2014 

ADDRESSES: A copy of this ICR with 

applicable supporting documentation; 

including a description of the likely 

respondents, proposed frequency of 

response, and estimated total burden 

may be obtained free of charge from the 

RegInfo.gov Web site at http://

www.reginfo.gov/public/do/

PRAViewICR?ref_nbr=201410-1225-001 

(this link will only become active on the 

day following publication of this notice) 

or by contacting Michel Smyth by 

telephone at 202–693–4129, TTY 202– 

693–8064, (these are not toll-free 

numbers) or by email at DOL_PRA_

PUBLIC@dol.gov. 

Submit comments about this request 

by mail or courier to the Office of 

Information and Regulatory Affairs, 

Attn: OMB Desk Officer for DOL–DM, 

Office of Management and Budget, 

Room 10235, 725 17th Street NW., 

Washington, DC 20503; by Fax: 202– 

395–5806 (this is not a toll-free 

number); or by email: OIRA_

submission@omb.eop.gov. Commenters 

are encouraged, but not required, to 

send a courtesy copy of any comments 

by mail or courier to the U.S. 

Department of Labor-OASAM, Office of 

the Chief Information Officer, Attn: 

Departmental Information Compliance 

Management Program, Room N1301, 

200 Constitution Avenue NW., 

Washington, DC 20210; or by email: 

DOL_PRA_PUBLIC@dol.gov. 

FOR FURTHER INFORMATION CONTACT: 

Contact Michel Smyth by telephone at 

202–693–4129, TTY 202–693–8064, 

(these are not toll-free numbers) or by 

email at DOL_PRA_PUBLIC@dol.gov. 

Authority: 44 U.S.C. 3507(a)(1)(D). 

SUPPLEMENTARY INFORMATION: This ICR 

seeks to extend PRA authority for the 

Equal Access to Justice Act (EAJA) 

information collection requirements for 

the DOL codified in regulations 29 CFR 

part 16, subpart B. The EAJA provides 

for payment of fees and expenses to 

eligible parties who have prevailed 

against an agency in certain 

administrative proceedings. In order to 

obtain an award, the statute and 

associated DOL regulations require the 

filing of an application. Other agencies 

may have their own EAJA regulations. 

This information collection is 

authorized under 5 U.S.C. 504(d)(1)(B). 

This information collection is subject 

to the PRA. A Federal agency generally 

cannot conduct or sponsor a collection 

of information, and the public is 

generally not required to respond to an 

information collection, unless it is 

approved by the OMB under the PRA 

and displays a currently valid OMB 

Control Number. In addition, 

notwithstanding any other provisions of 

law, no person shall generally be subject 

to penalty for failing to comply with a 

collection of information that does not 

display a valid Control Number. See 5 

CFR 1320.5(a) and 1320.6. The DOL 

obtains OMB approval for this 

information collection under Control 

Number 1225–0013. 

OMB authorization for an ICR cannot 

be for more than three (3) years without 

renewal, and the current approval for 

this collection is scheduled to expire on 

January 31, 2015. The DOL seeks to 

extend PRA authorization for this 

information collection for three (3) more 

years, without any change to existing 

requirements. The DOL notes that 

existing information collection 

requirements submitted to the OMB 

receive a month-to-month extension 

while they undergo review. For 

additional substantive information 

about this ICR, see the related notice 

published in the Federal Register on 

August 18, 2014 (79 FR 48770). 

Interested parties are encouraged to 

send comments to the OMB, Office of 

Information and Regulatory Affairs at 

the address shown in the ADDRESSES 

section within thirty (30) days of 

publication of this notice in the Federal 

Register. In order to help ensure 

appropriate consideration, comments 

should mention OMB Control Number 

1225–0013. The OMB is particularly 

interested in comments that: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

• Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

• Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

• Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Agency: DOL–DM. 

Title of Collection: Equal Access to 

Justice Act. 

OMB Control Number: 1225–0013. 

Affected Public: Individuals or 

Households; Private Sector—businesses 

or other for-profits, farms, and not-forprofit institutions; and State, Local, and 

Tribal Governments. 

Total Estimated Number of 

Respondents: 10. 

Total Estimated Number of 

Responses: 10. 

Total Estimated Annual Time Burden: 

50 hours. 

Total Estimated Annual Other Costs 

Burden: $23. 

mstockstill on DSK4VPTVN1PROD with NOTICES